Medical Coverage Policy: Cardiointegram (CIG) / Omnicardiogram
Policy governs coverage determination for Cardiointegram (CIG)/Omnicardiogram as a diagnostic technique to detect ECG abnormalities for Commercial products of Blue Cross & Blue Shield of Rhode Island. Medicare Advantage members are referred to related Medicare policies.
No material clinical or coverage changes in this revision.
Coverage Determination
Not Medically Necessary
Coverage determination for Commercial Products
May be proposed as a substitute for exercise tolerance testing with thallium imaging, but inadequately validated.
This policy applies to Commercial Products only. For members enrolled in Medicare Advantage plans, coverage is determined according to applicable Medicare national or local coverage determinations; see the Related Policies section for guidance.
Cardiointegram (CIG) / Omnicardiogram is considered not medically necessary for Commercial Products due to insufficient evidence demonstrating an effect on health outcomes. The following HCPCS code is listed as not medically necessary: S9025 (Omnicardiogram / cardiointegram).
Coding and Billing
| S9025 | Omnicardiogram / cardiointegram |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.